Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Trial details
- Registry ID
- NCT05877963
- Drugs studied
- Ublituximab
TrialRedline tracks 14 clinical trials sponsored by TG Therapeutics, Inc.: 4 Phase 3, 2 Phase 2 / 3, 8 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabNCT05877963 | Ublituximab | Recruiting | 2027-01-21Estimated |
| An Extension Study of Ublituximab in Participants With Relapsing Multiple SclerosisNCT04130997 | Ublituximab | Active not recruiting | 2032-05-31Estimated |
| A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)NCT07211633 | Ublituximab | Active not recruiting | 2026-10-31Estimated |
| Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic LeukemiaNCT02612311 | Chlorambucil, Obinutuzumab, TGR-1202, Ublituximab | Terminated | 2023-02-22Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple SclerosisNCT07220252 | Fingolimod, Ublituximab | Recruiting | 2030-01-01Estimated |
| Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)NCT03801525 | Ublituximab, Umbralisib, Venetoclax | Terminated | 2022-12-20Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2022-12-28Day | UblituximabTG Therapeutics, Inc. · TGTX | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA761238", "applicant_as_listed_by_fda": "TG THERAPEUTICS, INC", "brand_names": ["BRIUMVI"], "active_ingredients": ["UBLITUXIMAB-XIIY"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20221228", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |
Names as written in the registry records.
Before: 30 May 2027. After: 31 Jul 2027.
NCT05877963 · TG Therapeutics, Inc.
Before: 1 Dec 2027. After: 21 Jan 2027.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Part 2: Area under the curve (AUC) From Week 0 to Week 12 [AUC(0-W12)] of Ublituximab. After: Measure: Part 2: Area under the curve (AUC) at Steady State [AUCss] of Ublituximab.
Before: 31 Jul 2027. After: 30 May 2027.
NCT07220252 · TG Therapeutics, Inc.
Before: Not yet recruiting. After: Recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: 31 Dec 2026. After: 31 Oct 2026.
Before: Recruiting. After: Active not recruiting.
NCT04130997 · TG Therapeutics, Inc.
Before: 1 Feb 2030. After: 31 May 2032.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Area under the curve (AUC) from 0 to Week 24 of Ublituximab. After: Measure: Area Under the Curve From Week 0 to Week 24 (AUC0-W24) of Ublituximab.
NCT05877963 · TG Therapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Part A: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48 Measure: Part B: Area Under the Curve Over the First 16 Weeks (AUC0-W16) of Ublituximab. After: Measure: Part A and Part C: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48 Measure: Part B: Area Under the Curve Over the First 16 Weeks (AUC0-W16) of Ublituximab.
Before: 1 Sep 2026. After: 1 Dec 2027.
NCT05877963 · TG Therapeutics, Inc.
Before: 600 participants (planned). After: 800 participants (planned).
Before: 1 Mar 2026. After: 1 Sep 2026.